Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, ...

Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer!

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

After 6 months of hormone therapy, men with prostate cancer showed worsening lipid profiles, with 21% showing increased risk of cardiovascular disease based on general population tools. Men receiving ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, ...